BCL2L1 and ovarian carcinoma: However, Petigny-Lechartier et al. showed that although AZD8055 reduces MCL-1/BH3-only protein ratio by modulating MCL-1 and PUMA, AZD8055 does not efficiently sensitize ovarian cancer cells to ABT-737 (BCL-2, BCL-xL and BCL-w antagonist)51.